Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII).
The mechanism by which negatively charged substances such as celite, kaolin, or ellagic acid contribute to the surface-dependent activation of Hageman factor (Factor XII) was studied. Kinetic studies of the proteolytic activation of (125)I-labeled human Hageman factor by human plasma kallikrein, plasma, activated Factor XI, and trypsin were performed in the presence and absence of high molecular weight kininogen and surface materials such as celite, kaolin, or ellagic acid. The results showed that surface-bound Hageman factor was 500 times more susceptible than soluble Hageman factor to proteolytic activation by kallikrein in the presence of high molecular weight kininogen. Surface binding of Hageman factor enhanced its cleavage by plasmin, activated Factor XI, and trypsin by 100-fold, 30-fold, and 5-fold, respectively. On a molar basis, trypsin was twice as potent as kallikrein in the cleavage of the surface-bound Hageman factor, while plasmin and activated Factor XI were an order of magnitude less potent than kallikrein. Kallikrein even at concentrations as low as 0.5 nM (i.e., 1/1000th of the concentration of prekallikrein in plasma) was very potent in the limited proteolysis of the surface-bound Hageman factor. These results suggest that substances classically known as "activating surfaces" promote the activation of Hageman factor indirectly by altering its structure such that it is much more susceptible to proteolytic activation by other plasma or cellular proteases.
D000327:Adsorption; D000838:Anions; D004610:Ellagic Acid; D005172:Factor XI / Q000378:metabolism; D005174:Factor XII / Q000378:metabolism*; D007610:Kallikreins / Q000378:metabolism; D007616:Kaolin; D007704:Kininogens / Q000378:metabolism; D008970:Molecular Weight; D010446:Peptide Fragments / Q000378:metabolism; D013499:Surface Properties; D014357:Trypsin / Q000378:metabolism
D000838:Anions; D007704:Kininogens; D010446:Peptide Fragments; D004610:Ellagic Acid; D007616:Kaolin; D005174:Factor XII; D005172:Factor XI; D007610:Kallikreins; D014357:Trypsin
J Lab Clin Med. 1978 Jan;91(1):148-55
73563
J Clin Invest. 1975 Dec;56(6):1663-72
127805
Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683-7
266208
Proc Natl Acad Sci U S A. 1977 Oct;74(10):4636-40
270705
J Exp Med. 1978 Mar 1;147(3):719-29
632748
J Clin Invest. 1977 Jun;59(6):1167-75
864009
J Clin Invest. 1977 Jul;60(1):18-31
874082
J Biol Chem. 1977 Sep 25;252(18):6432-7
893417
Biochemistry. 1977 Sep 20;16(19):4182-8
901768
J Biol Chem. 1976 Aug 25;251(16):4749-802
956165
Proc Natl Acad Sci U S A. 1976 Aug;73(8):2554-8
1066663
J Clin Invest. 1975 Nov;56(5):1082-92
1184736
J Clin Invest. 1975 Dec;56(6):1650-62
1202089
J Lab Clin Med. 1976 Feb;87(2):327-37
1245795
J Biol Chem. 1973 Nov 25;248(22):7742-7
4127217
Int Arch Allergy Appl Immunol. 1966;29(2):185-9
4160044
J Exp Med. 1971 Apr 1;133(4):696-712
4251126
Proc Soc Exp Biol Med. 1971 Dec;138(3):959-66
4257083
J Exp Med. 1973 Dec 1;138(6):1564-83
4271629
Proc Natl Acad Sci U S A. 1972 Sep;69(9):2442-5
4506766
J Clin Invest. 1974 Jul;54(1):43-53
4600045
Biochemistry. 1973 Jan 30;12(3):420-6
4683488
J Exp Med. 1973 Dec 1;138(6):1345-55
4762550
Circ Res. 1974 May;34(5):641-51
4826936
J Biol Chem. 1971 Nov;246(21):6661-5
5167250
Prog Hematol. 1966;5:204-45
5337570
Blood. 1965 Nov;26(5):521-32
5845778
Proc Soc Exp Biol Med. 1953 Jan;82(1):171-4
13037836
J Physiol. 1958 Nov 10;144(1):1-22
13599105
Ann N Y Acad Sci. 1963 Feb 4;104:133-45
13933028
J Clin Invest. 1955 Apr;34(4):602-13
14367514
Thromb Diath Haemorrh. 1959 Sep 1;3:593-603
14427142
J Clin Invest. 1975 May;55(5):1082-9
16695963